190 related articles for article (PubMed ID: 26214645)
1. Gefitinib causes growth arrest and inhibition of metastasis in human chondrosarcoma cells.
Song J; Zhu J; Zhao Q; Tian B
J BUON; 2015; 20(3):894-901. PubMed ID: 26214645
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
[TBL] [Abstract][Full Text] [Related]
3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
6. Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis.
Tzeng HE; Chen PC; Lin KW; Lin CY; Tsai CH; Han SM; Teng CL; Hwang WL; Wang SW; Tang CH
Clin Sci (Lond); 2015 Jul; 129(2):147-58. PubMed ID: 25735814
[TBL] [Abstract][Full Text] [Related]
7. IGF-I enhances α5β1 integrin expression and cell motility in human chondrosarcoma cells.
Wu CM; Li TM; Hsu SF; Su YC; Kao ST; Fong YC; Tang CH
J Cell Physiol; 2011 Dec; 226(12):3270-7. PubMed ID: 21344385
[TBL] [Abstract][Full Text] [Related]
8. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
11. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
12. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Angelucci A; Gravina GL; Rucci N; Millimaggi D; Festuccia C; Muzi P; Teti A; Vicentini C; Bologna M
Endocr Relat Cancer; 2006 Mar; 13(1):197-210. PubMed ID: 16601288
[TBL] [Abstract][Full Text] [Related]
13. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Tan TW; Lai CH; Huang CY; Yang WH; Chen HT; Hsu HC; Fong YC; Tang CH
J Cell Biochem; 2009 May; 107(2):345-56. PubMed ID: 19301259
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
15. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
17. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
Sevelda F; Mayr L; Kubista B; Lötsch D; van Schoonhoven S; Windhager R; Pirker C; Micksche M; Berger W
J Exp Clin Cancer Res; 2015 Nov; 34():134. PubMed ID: 26526352
[TBL] [Abstract][Full Text] [Related]
18. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells.
Song J; Wang X; Zhu J; Liu J
J BUON; 2016; 21(1):244-51. PubMed ID: 27061554
[TBL] [Abstract][Full Text] [Related]
20. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
